Toufan Parman, Ph.D., D.A.B.T., Senior Director of Nonclinical Safety Evaluations at Sangamo Therapeutics. Dr. Parman currently manages the Pharmacology, Toxicology, and Pharmacokinetic Program at Sangamo Therapeutics. In addition, as the nonclinical lead on various gene and cell therapy programs, Dr. Parman provides preclinical drug development and safety assessment support for these projects. She has expertise in developing and implementing preclinical plans in support of IND submissions and has successfully written and submitted two INDs and has put two novel male contraceptives into clinical trials.
Dr. Parman has over 20 years’ experience in preclinical drug development translating novel therapeutics from discovery to clinic. She has managed, designed, developed and conducted efficacy, general and reproductive toxicology, and PK studies as well as specialized mechanistic studies in various animal models for a wide variety of pharmaceutical products including but not limited to chemotherapeutic agents, vaccines, contraceptives, monoclonal antibodies, proteins, gene, and cell-based therapies. She has produced seminal results and contributed both conceptually and technically to her fields of expertise, as demonstrated by her publications. Dr. Parman has broad technical proficiency in chemistry, neurotoxicology, molecular and cell biology, pharmacology, and reproductive and general toxicology. As a result, she can integrate molecular and cellular approaches to assess pharmacological outcomes for novel therapeutics.
She has significant experience in managing projects involving preparation, analytical testing, and formulation of drug substances, active pharmaceutical ingredients (API), and clinical manufacturing of novel therapeutics.
Dr. Parman received her B.Sc. with honors in Chemistry from Dalhousie University (Nova Scotia, Canada), her M.Sc. in Physical Organic Chemistry, and her Ph.D. in Pharmaceutical Sciences from the University of Toronto. Dr. Parman’s graduate work focused on drug metabolism and disposition and mechanistic reproductive toxicology. She received a Postdoctoral Fellowship Award to work at the Laboratory of Cellular Oncology at the NCI to pursue training in the area of cell signaling and cancer. Dr. Parman continued her postdoctoral training in the area of cell signaling and cancer at the School of Medicine, Department of Hepatology and Gastroenterology, Stanford University.
Dr. Parman joined Sangamo Therapeutics in 2021. Prior to that She worked at SRI International from 2005-2021 during which she served as a Toxicology Study Director, Associate Director of Mammalian toxicology, and Director of Toxicology and Immunology Service. She has developed and filed a patent on a novel method for delivery of stem cells to the brain via the nasal passages. Dr. Parman has been certified by the American Board of Toxicology since 2007.